1,432 press releases in English indexed under industrial.
Pella Corporation is expanding technical career pathways through connected manufacturing technology that supports made-to-order quality and customization.
Boost ROI through lightweight composites that cut fuel and operating costs, automated manufacturing that scales output, and expansion into eVTOL, UAV and hypersonic applications. Boost ROI through lightweight composites that cut fuel and operating costs, automated manufacturing that scales output, and expansion into eVTOL, UAV and hypersonic applications.
The global trisodium citrate market is gaining steady momentum as food and beverage manufacturers, pharmaceutical companies, and industrial producers seek versatile ingredients for product formulation and processing. Trisodium citrate, also known as sodium citrate, is the sodium salt of citric ... Read more
JOLIET, Ill., October 22, 2026--Hyundai Translead today announced plans to increase its investment in its new Illinois manufacturing operations to $600 million and expand its job commitment to 3,750 full-time positions. Hyundai Translead initially announced in March that it would invest more than $450 million to establish two advanced manufacturing facilities in Will County, creating 2,500 full-ti
The global sizing agents market is gaining momentum as manufacturers across the paper, packaging, textile, and coatings industries seek materials that improve product quality, durability, and production efficiency. Sizing agents are specialty chemicals used to control the absorption of liquids, ... Read more
The global Self-adhesive protective films Market play an important role in protecting product surfaces from scratches, dust, abrasion, and damage during manufacturing, transportation, storage, and installation. These films are widely used across automotive, electronics, construction, metal processing, and other industrial ... Read more
Falconi US, a Chicago-based management consulting firm focused on manufacturing, has partnered with Celonis to help manufacturing and energy companies in the United States turn process data into operational results. Falconi US consultants will work alongside Celonis teams on customer...
Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new operational technology (OT) security solution for industrial equipment, leveraging the world-class OT cybersecurity technologies of Nozomi Networks, Inc., a U.S.-based company that became a wholly owned subsidiary of Mitsubishi Electric in January 2026. The solution will enable industrial equipment manufacturers to implement stronger cybersecurity measures and end users to operate facilities and eq... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363189
Wamkele Mene, Secretary General of the African Continental Free Trade Area (AfCFTA) Secretariat, has been confirmed as a keynote speaker at South Sudan Oil & Power (SSOP) 2026, taking place November 24–25 in Juba. His participation comes as South Sudan deepens petroleum and infrastructure ties with regional neighbors, bringing the country’s energy investment agenda into a broader discussion around regional trade, market access and economic integration. Mene’s participation follows his July 2026 visit to Juba, during which he engaged with government and private-sector stakeholders on South Sudan’s pathway toward AfCFTA ratification and the opportunities presented by the continental market. The country signed the AfCFTA agreement in 2018. During the visit, South Sudanese authorities highlighted the role of the platform in strengthening private-sector participation, supporting SME growth and advancing broader trade and regional ties. For South Sudan, AfCFTA membership stands to advance regional integration across an energy sector that is inherently dependent on cross-border trade and infrastructure. As a landlocked oil producer, the country relies on pipelines through Sudan to move crude to international markets, while neighboring countries provide important routes for petroleum imports, equipment, services and logistics. Recent disruptions have highlighted the commercial risks associated with this dependence. Damage to export infrastructure in Sudan disrupted South Sudanese crude flows in 2024, while the government has sought to strengthen complementary regional supply routes. In 2025, South Sudan and Kenya established a framework for petroleum-product imports through the Port of Mombasa and Northern Corridor, including access to pipeline and storage infrastructure. AfCFTA membership would add a trade and investment dimension to these physical regional connections. Ratification would enable qualifying South Sudanese businesses to trade under the Agreement’s preferential framework, potentially reducing barriers to the movement of goods and services required by the energy industry while improving access to markets across the continent. This regional integration agenda provides a strong backdrop to SSOP 2026. South Sudan is targeting an increase in oil production from approximately 170,000 barrels per day (bpd) to 230,000 bpd in the short term and 450,000 bpd over the longer term. Reaching these targets will require investment not only in exploration and mature-field redevelopment, but also in the infrastructure, services and regional commercial relationships needed to support higher production and connect projects with markets. Mene’s participation will bring this continental trade and investment perspective to SSOP 2026. Held under the theme Resource Renaissance – Energy-Fueled Growth for a New Generation, the conference will connect government, operators, investors, financiers and service companies as South Sudan seeks to translate energy investment into wider industrial and economic growth. Now in its seventh edition, SSOP has a proven track record of converting high-level engagement into actionable commercial and cross-border partnerships. The event has facilitated landmark agreements spanning exploration, production and infrastructure cooperation with regional partners such as Djibouti and South Africa. To register for South Sudan Oil & Power 2026 in Juba on November 24–25, visit: https://apo-opa.co/4i84D8d Distributed by APO Group on behalf of Energy Capital & Power.
Silicone Sealants Market Report The Business Research Company The Business Research Company’s The Silicone Sealants Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 22, 2026 / EINPresswire.com / -- The silicone sealants market has been experiencing notable growth recently, driven by a variety of expanding industrial and construction needs. With in
Funds will support next-generation semiconductor research and development in Everett, Washington, enabling substantial power module manufacturing capability in Washington state. Project will also support research and development for domestic next-generation semiconductor tooling. EVERETT, Wash., October 22, 2026 --( BUSIN
TORONTO, ONTARIO - October 22, 2026 - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults. The Company has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS. The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release. Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera. The Company is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term. SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110's efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs. About NeuroThera Labs Inc. NeuroTheraLabsInc. (TSXV:NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. For further information, please contact: Michal Efraty IR Manager NeuroThera Labs Inc. Telephone: +972-3-7617108 Email: michal@efraty.com Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Notice on Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information in this news release includes statements regarding: the initiation of patient enrollment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the ability of the Company to progress toward patient enrollment for its Phase IIb clinical trial for TS; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca). The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.